Tingyu-Yi

Tingyu-Yi is a biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company specifically focuses on molecular glue degraders, a modality designed to eliminate "undruggable" proteins by facilitating their interaction with E3 ubiquitin ligases. Founded by Dr. Tingyu Yi, a prominent scientist with extensive experience in TPD research at H3 Biomedicine, the firm leverages a proprietary platform to identify high-affinity small molecules. Their current research pipeline is primarily directed toward addressing unmet needs in oncology and immunology. Tingyu-Yi has successfully raised capital from leading venture firms, including Qiming Venture Partners and Lilly Asia Ventures, to accelerate its pre-clinical programs.